Figure S1. (A) Statistical analysis of p-Akt levels in U87MG and LN229 cells treated with GC or NE with or without Akt signaling inhibitor (perifosine, 10 μmol/l). (B) mRNA expression levels of AKT1 and AKT2 in U87MG and LN229 cells after siRNA intervention. (C) Western blot assay and statistical analysis of PI3K/Akt signaling-related proteins in U87MG and LN229 cells treated with siRNA targeting Akt. (D) Cell Counting Kit-8 results of U87MG and LN229 cells treated with siRNA targeting Akt. **P<0.01. p-, phosphorylated; GC, glucocorticoid; NE, norepinephrine; PI3K, phosphatidylinositol 3-kinase; si-, small interfering; n.s., no significance.



Figure S2. (A) U87MG and LN229 cells treated with GC, NE, or DMSO in the presence or absence of an Akt signaling inhibitor (perifosine, 10 μmol/l) were subjected to colony formation assays. Ratios are presented. (B) U87MG and LN229 cells treated with GC, NE, or DMSO in the presence or absence of an Akt signaling inhibitor (perifosine, 10 μmol/l) were subjected to cell cycle assays. **P<0.01. GC, glucocorticoid; NE, norepinephrine; p-, phosphorylated.



Figure S3. Western blot assay and statistical analysis of p-Akt levels in U87MG and LN229 cells treated with NE with or without ADRB1 antagonist (atenolol, 0.25 μmol/l) or ADRB2 antagonist (hydrochloride, 0.7 μmol/l). **P<0.01. p-, phosphorylated; NE, norepinephrine; ADRB, β-adrenergic receptor; ate, atenolol; hyd, hydrochloride.



Figure S4. (A) mRNA expression levels of ADRB1 and ADRB2 in U87MG and LN229 cells after siRNA intervention. (B) Western blot assay and statistical analysis of PI3K/Akt signaling-related proteins in U87MG and LN229 cells treated with siRNAs targeting ADRB1/2. **P<0.01. ADRB, β-adrenergic receptor; p-, phosphorylated; NE, norepinephrine.